Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04478474 · ClinicalTrials.gov registry record
Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
A clinical trial, sponsored by New York Medical College.
- Completed
- Registry status
- 100
- Enrollment target
NCT04478474: Completed study, sponsored by New York Medical College.
NCT04478474 is a clinical trial that has completed, run by New York Medical College. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04478474 has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
The primary objective is to determine the incidence of CMV viremia and disease in pediatric allogeneic stem cell transplantation recipients who received ganciclovir prophylaxis up until day +100 by retrospective analysis.
Primary Outcome
Ganciclovir will be safe, well tolerated, and effective to prevent CMV viremia and/or decrease in pediatric allogeneic stem cell transplant recipients.
Interventions
- DRUG Ganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2022-09-15 |
What the finished NCT04478474 record still lists
NCT04478474 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Ganciclovir is the first listed.
NCT04478474 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04478474 about?
NCT04478474 is a clinical study titled "Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients". The primary objective is to determine the incidence of CMV viremia and disease in pediatric allogeneic stem cell transplantation recipients who received ganciclovir prophylaxis up until day +100 by retrospective analysis.
What is the current status of trial NCT04478474?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2020-09-15. Estimated completion is 2022-09-15.
What interventions are being tested in trial NCT04478474?
The interventions under investigation include: Ganciclovir (DRUG).
Who is sponsoring clinical trial NCT04478474?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI